127 patients underwent prostate biopsy, with 94 prostate cancers diagnosed; 86.2 percent had clinically significant disease
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 (HealthDay News) — A “Man Van” deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Masood Moghul, M.B.B.S., from the Institute of Cancer Research in London and colleagues moved a bespoke nurse-led mobile clinical unit to community-based locations in areas of high deprivation indices in London with targeted invitations to high-risk men. Participants were offered prostate-specific antigen tests and a general health check.
Overall, 3,379 men attended a Man Van clinic between January 2023 and January 2024 (nonattendance rate, 15.1 percent). The researchers found that 310 men were referred for prostate cancer investigations and 262 underwent prostate magnetic resonance imaging (MRI) scans. Of the MRIs, 53.1, 13.4, and 32.4 percent had a Prostate Imaging Reporting and Data Systems score of 1/2, 3, and 4/5, respectively. One hundred twenty-seven patients underwent prostate biopsy, with 94 prostate cancers diagnosed (74.0 percent of biopsies); 86.2 percent were cancers with clinically significant disease (grade group 2 or higher). For clinically significant disease, the overall diagnostic rate was 2.8 percent. At presentation, no prostate cancers were metastatic. Of the men diagnosed with prostate cancer, 26.6, 2.1, 2.1, 41.5, and 27.7 percent were managed with active surveillance, cryotherapy, low dose-rate brachytherapy, robotic prostatectomy, and radiotherapy, respectively.
“Testing those men resulted in high rates of diagnosis of clinically significant prostate cancer, illustrating the effectiveness of a mobile facility for detecting prostate cancer in these groups,” Moghul said in a statement.
Two authors disclosed ties to the biopharmaceutical industry.
Copyright © 2025 HealthDay. All rights reserved.
